Polyinosinic-polycytidylic acid
产品说明书
 |
同义名 : | 聚胞苷酸 ;Poly(I:C) |
| CAS号 : | 24939-03-5 | |
| 货号 : | A719383 | |
| 分子式 : | (C10H13N4O8P)x.(C9H14N3O8P)x | |
| 纯度 : | 90% | |
| 分子量 : | 0 | |
| MDL号 : | MFCD00131957 | |
| 存储条件： |
Pure form Inert atmosphere,Store in freezer, under -20°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
H2O: 50 mg/mL，配合低频超声助溶 |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Toll-like receptor-3 (TLR-3) belong to the Toll-like receptors family, it is mainly expressed on immune cells where it senses pathogen-associated molecular patterns and initiates innate immune response[3]. Polyinosinic-polycytidylic acid [poly (I:C)] can act as a dsRNA molecule and interacts with TLR-3 of microglia cells to evoke the immune system, thus mimicking the viral infection. Early life exposure to poly (I:C) has a long-term effect and impairs learning and memory, probably through TNF-α mediated neuroinflammation and alteration in the expression of memory associated genes in frontal cortex and hippocampus of rats[4]. Poly (I:C) exclusively stimulated the expression of interferon (IFN) β, IFNλ1, and the IFN-stimulated gene OAS2. Poly (I:C) also significantly increased secretion of elafin, CCL20, and RANTES. Secretions from poly (I:C)-treated fibroblasts had both greater anti-HIV activity and induced higher levels of CD4 + T cell chemotaxis than those from LPS-treated cells[5]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT01245673 | Myeloma | Phase 2 | Active, not recruiting | August 2018 | United States, Maryland ... 展开 >> University of Maryland Greenebaum Cancer Center Baltimore, Maryland, United States, 21201 United States, Pennsylvania Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 收起 << |
| NCT02425306 | Melanoma | Phase 1 Phase 2 | Terminated(Slow accrual to par... 展开 >>t 2 of the study. Accrual to part 1 is complete.) 收起 << | - | United States, Virginia ... 展开 >> Cancer Center at the University of Virginia Charlottesville, Virginia, United States, 22908 收起 << |
| NCT03121677 | Follicular Lymphoma | Phase 1 | Recruiting | January 31, 2028 | United States, Missouri ... 展开 >> Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Todd A Fehinger, M.D., Ph.D. 314-362-5654 tfehnige@wustl.edu Principal Investigator: Todd A Fehniger, M.D., Ph.D. Sub-Investigator: Neha Mehta-Shah, M.D. Sub-Investigator: Jeffrey Ward, M.D., Ph.D. Sub-Investigator: Nancy L Bartlett, M.D. Sub-Investigator: Brad Kahl, M.D. Sub-Investigator: Amanda Cashen, M.D. Sub-Investigator: Armin Ghobadi, M.D. Sub-Investigator: John DiPersio, M.D., Ph.D. Sub-Investigator: William E Gillanders, M.D. Sub-Investigator: Malachi Griffith, Ph.D. Sub-Investigator: Obi Griffith, Ph.D. Sub-Investigator: Max Artyomov, Ph.D. 收起 << |
| 参考文献 |
|---|